Aralen

Formulated to treat malaria to mitigate parasitic infection in the blood.

Strengths: 250 · 500mg

Medicine details

Conditions
Alternative names

Avloclor; Nivaquine

Therapeutic class

Antimalarial

Pharmacological class

Aminoquinoline

Known off-label uses

rheumatoid arthritis; systemic lupus erythematosus

Contraindications

retinal damage; hypersensitivity; pre-existing visual field changes

Minor side effects

nausea; headache; diarrhoea

Moderate side effects

skin pigmentation; rash; visual disturbance

Dosage forms

Tablet

Administration route

Oral use

Patient summary

Formulated to treat malaria to mitigate parasitic infection in the blood.

Prescription status

POM

Manufacturer

Sanofi

Onset Time

1–2 hours

Duration

varies by treatment length

Storage instructions

Store below 25°C.

Drug interactions

Ciclosporin; Tamoxifen

Age restrictions

Safe for use in children if dosed by weight.

Precautions and warnings

routine eye examinations required; use with caution in psoriasis; may cause cardiac conduction issues

Serious side effects

retinopathy — requires immediate medical attention; qt interval prolongation — requires immediate medical attention

Mechanism of action

This medication functions by interfering with the growth of parasites in the red blood cells, effectively eradicating the malaria-causing organisms.

Pregnancy and breastfeeding

Pregnancy: Use is acceptable for malaria treatment where benefit outweighs risk. Breastfeeding: Safe in recommended doses.

Aralen

Formulated to treat malaria to mitigate parasitic infection in the blood.

Editorial Notes

  • Active ingredient(s): Chloroquine
  • Listed indication(s): Malaria

Usually available as

  • 180 tablets - 250 mg268-250-mg-2038
  • 90 tablets - 500 mg268-500-mg-2042